An international team of researchers supported by the National Institutes of Health (NIH) has blocked staph infections in mice using a drug previously tested in clinical trials as a cholesterol-lowering agent. The novel approach, described in the February 14 online edition of Science, could offer a new direction for therapies against a bacterium thats becoming increasingly resistant to antibiotics.
By following their scientific instinct about a basic biological process, the researchers made a surprising discovery with important clinical implications, said NIH Director Elias A. Zerhouni, M.D. Although the results are still very preliminary, they offer a promising new lead for developing drugs to treat a very timely and medically important health concern.
This work was supported by three NIH components: the National Institute of General Medical Sciences, the National Institute of Allergy and Infectious Diseases, and the National Institute of Child Health and Human Development.
A pigment similar to the one that gives carrots their color turns Staphylococcus aureus (staph) golden. In the bacterium, this pigment acts as an antioxidant to block the reactive oxygen molecules the immune system uses to kill bacteria.
Researchers had speculated that blocking pigment formation in staph could restore the immune systems ability to thwart infection. While perusing a magazine on microbial research, Eric Oldfield, Ph.D., of the University of Illinois at Urbana-Champaign read how in 2005 University of California, San Diego researchers knocked out a gene in staphs pigment-making pathway to create colorlessand less pathogenicbacteria.
I looked at the metabolic pathway and noticed that it was similar to the one for the production of cholesterol in humans, said Oldfield, senior author of the Science paper, who had spent decades studying this pathway. With numerous cholesterol-lowering drugs already on the market and in development, he wondered if any could turn staph colorless and make them once again susceptible to the immune system.
Colleagues in Taiwan determined the structure of the enzyme that triggers the first critical step in staphs pigment formation and observed striking similarities to an enzyme involved in human cholesterol production. They also captured the structures of several cholesterol-lowering drugs bound to the bacterial enzyme.
Building on their 2005 research that sparked the current study, Victor Nizet, M.D., and George Liu, M.D., Ph.D., now at Cedars-Sinai Medical Center in Los Angeles, Calif., tested eight different drug compounds that act on the human cholesterol enzyme. Three blocked pigment production in laboratory tests. When the researchers treated mice infected with S. aureus with one of the compounds, the bacterial population was reduced by 98 percent.
Because the approach reduces the virulence of the bacteria by stopping pigment production, it may not cause selective pressures on the population, which can lead to antibiotic resistance. It also targets only S. aureus, possibly reducing side effects.
This is an entirely new approach that seems to work in animals, and now we need to take the next step to explore if it will work in humans, said Oldfield.
|Contact: Emily Carlson|
NIH/National Institute of General Medical Sciences